These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 38005859)

  • 41. Burden of COVID-19 and Vaccination Coverage in the Italian Population as of October 2021.
    Altobelli E; Marzi F; Angelone AM; Mazzocca R; Mastrodomenico M; Petrocelli R; Marziliano C
    Int J Environ Res Public Health; 2022 Jan; 19(1):. PubMed ID: 35010756
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [COVID-19 vaccination at the University of Alicante (Spain): detection of neutralizing antibodies against SARS-CoV-2 by rapid serological test, a cross-sectional study].
    Montagud AC; Vicente-Alcalde N; Gabaldón-Bravo EM; Hurtado-Sánchez JA; Montagud E; Egoavil CM; Chavarría-Alarcón E; Caballero P; Tuells J
    Rev Esp Salud Publica; 2023 Dec; 97():. PubMed ID: 38126466
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Correlation between vaccine coverage and the COVID-19 pandemic throughout the world: Based on real-world data.
    Huang C; Yang L; Pan J; Xu X; Peng R
    J Med Virol; 2022 May; 94(5):2181-2187. PubMed ID: 35075651
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety and humoral response rate of inactivated and mRNA vaccines against SARS-CoV-2 in patients with Multiple Sclerosis.
    Ciampi E; Uribe-San-Martin R; Soler B; García L; Guzman J; Pelayo C; Jürgensen L; Guzman I; Vera F; Galleguillos L; Cárcamo C
    Mult Scler Relat Disord; 2022 Mar; 59():103690. PubMed ID: 35182880
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Evaluation of a COVID-19 Vaccine Campaign and SARS-CoV-2 Infection and Mortality Among Adults Aged 60 Years And Older in a Middle-Income Country.
    Macchia A; Ferrante D; Angeleri P; Biscayart C; Mariani J; Esteban S; Tablado MR; de Quirós FGB
    JAMA Netw Open; 2021 Oct; 4(10):e2130800. PubMed ID: 34714342
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Individual preferences for COVID-19 vaccination in China.
    Leng A; Maitland E; Wang S; Nicholas S; Liu R; Wang J
    Vaccine; 2021 Jan; 39(2):247-254. PubMed ID: 33328140
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial.
    Kremsner PG; Ahuad Guerrero RA; Arana-Arri E; Aroca Martinez GJ; Bonten M; Chandler R; Corral G; De Block EJL; Ecker L; Gabor JJ; Garcia Lopez CA; Gonzales L; Granados González MA; Gorini N; Grobusch MP; Hrabar AD; Junker H; Kimura A; Lanata CF; Lehmann C; Leroux-Roels I; Mann P; Martinez-Reséndez MF; Ochoa TJ; Poy CA; Reyes Fentanes MJ; Rivera Mejia LM; Ruiz Herrera VV; Sáez-Llorens X; Schönborn-Kellenberger O; Schunk M; Sierra Garcia A; Vergara I; Verstraeten T; Vico M; Oostvogels L;
    Lancet Infect Dis; 2022 Mar; 22(3):329-340. PubMed ID: 34826381
    [TBL] [Abstract][Full Text] [Related]  

  • 48. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
    Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
    Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Incidence of diabetes following COVID-19 vaccination and SARS-CoV-2 infection in Hong Kong: A population-based cohort study.
    Xiong X; Lui DTW; Chung MSH; Au ICH; Lai FTT; Wan EYF; Chui CSL; Li X; Cheng FWT; Cheung CL; Chan EWY; Lee CH; Woo YC; Tan KCB; Wong CKH; Wong ICK
    PLoS Med; 2023 Jul; 20(7):e1004274. PubMed ID: 37486927
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Burden of SARS-CoV-2 infection in healthcare workers during second wave in England and impact of vaccines: prospective multicentre cohort study (SIREN) and mathematical model.
    Pople D; Monk EJM; Evans S; Foulkes S; Islam J; Wellington E; Atti A; Hope R; Robotham J; Hopkins S; Brown CS; Hall VJ;
    BMJ; 2022 Jul; 378():e070379. PubMed ID: 35858689
    [TBL] [Abstract][Full Text] [Related]  

  • 51. SARS-CoV-2 variants and the global pandemic challenged by vaccine uptake during the emergence of the Delta variant: A national survey seeking vaccine hesitancy causes.
    AlJamaan F; Temsah MH; Alhasan K; Alenezi S; Alhaboob A; Alrabiaah A; Batais M; Alshahrani F; Assiri RA; Bafaqih H; Alaraj A; Al Qadrah B; Alhaidary A; Saad K; Saddik B; Halwani R; Rabaan AA; Al-Subaie S; Barry M; Al-Tawfiq JA
    J Infect Public Health; 2022 Jul; 15(7):773-780. PubMed ID: 35728424
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
    Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Persistence of immune responses after heterologous and homologous third COVID-19 vaccine dose schedules in the UK: eight-month analyses of the COV-BOOST trial.
    Liu X; Munro APS; Wright A; Feng S; Janani L; Aley PK; Babbage G; Baker J; Baxter D; Bawa T; Bula M; Cathie K; Chatterjee K; Dodd K; Enever Y; Fox L; Qureshi E; Goodman AL; Green CA; Haughney J; Hicks A; Jones CE; Kanji N; van der Klaauw AA; Libri V; Llewelyn MJ; Mansfield R; Maallah M; McGregor AC; Minassian AM; Moore P; Mughal M; Mujadidi YF; Belhadef HT; Holliday K; Osanlou O; Osanlou R; Owens DR; Pacurar M; Palfreeman A; Pan D; Rampling T; Regan K; Saich S; Saralaya D; Sharma S; Sheridan R; Stokes M; Thomson EC; Todd S; Twelves C; Read RC; Charlton S; Hallis B; Ramsay M; Andrews N; Lambe T; Nguyen-Van-Tam JS; Cornelius V; Snape MD; Faust SN;
    J Infect; 2023 Jul; 87(1):18-26. PubMed ID: 37085049
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Differential Antibody Response to mRNA COVID-19 Vaccines in Healthy Subjects.
    Wheeler SE; Shurin GV; Yost M; Anderson A; Pinto L; Wells A; Shurin MR
    Microbiol Spectr; 2021 Sep; 9(1):e0034121. PubMed ID: 34346750
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Model-Estimated Association Between Simulated US Elementary School-Related SARS-CoV-2 Transmission, Mitigation Interventions, and Vaccine Coverage Across Local Incidence Levels.
    Giardina J; Bilinski A; Fitzpatrick MC; Kendall EA; Linas BP; Salomon J; Ciaranello AL
    JAMA Netw Open; 2022 Feb; 5(2):e2147827. PubMed ID: 35157056
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Double-Blind, Randomized, Placebo-Controlled Phase III Clinical Trial to Evaluate the Efficacy and Safety of treating Healthcare Professionals with the Adsorbed COVID-19 (Inactivated) Vaccine Manufactured by Sinovac - PROFISCOV: A structured summary of a study protocol for a randomised controlled trial.
    Palacios R; Patiño EG; de Oliveira Piorelli R; Conde MTRP; Batista AP; Zeng G; Xin Q; Kallas EG; Flores J; Ockenhouse CF; Gast C
    Trials; 2020 Oct; 21(1):853. PubMed ID: 33059771
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunogenicity and safety of mixed COVID-19 vaccine regimens in patients with immune-mediated inflammatory diseases: a single-centre prospective cohort study.
    Hitchon CA; Mesa C; Bernstein CN; Marrie RA; Card C; O'Brien SF; Kim J
    BMJ Open; 2023 May; 13(5):e071397. PubMed ID: 37253487
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The representative COVID-19 cohort Munich (KoCo19): from the beginning of the pandemic to the Delta virus variant.
    Le Gleut R; Plank M; Pütz P; Radon K; Bakuli A; Rubio-Acero R; Paunovic I; Rieß F; Winter S; Reinkemeyer C; Schälte Y; Olbrich L; Hannes M; Kroidl I; Noreña I; Janke C; Wieser A; Hoelscher M; Fuchs C; Castelletti N;
    BMC Infect Dis; 2023 Jul; 23(1):466. PubMed ID: 37442952
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial.
    Mallory RM; Formica N; Pfeiffer S; Wilkinson B; Marcheschi A; Albert G; McFall H; Robinson M; Plested JS; Zhu M; Cloney-Clark S; Zhou B; Chau G; Robertson A; Maciejewski S; Hammond HL; Baracco L; Logue J; Frieman MB; Smith G; Patel N; Glenn GM;
    Lancet Infect Dis; 2022 Nov; 22(11):1565-1576. PubMed ID: 35963274
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Risk of myocarditis and pericarditis after a COVID-19 mRNA vaccine booster and after COVID-19 in those with and without prior SARS-CoV-2 infection: A self-controlled case series analysis in England.
    Stowe J; Miller E; Andrews N; Whitaker HJ
    PLoS Med; 2023 Jun; 20(6):e1004245. PubMed ID: 37285378
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.